Pacira BioSciences
PCRX
208 hedge funds and large institutions have $3.76B invested in Pacira BioSciences in 2014 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 18 closing their positions.
100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 18
20% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 69
9% more funds holding
Funds holding: 191 → 208 (+17)
8% more capital invested
Capital invested by funds: $3.48B → $3.76B (+$281M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
18% less call options, than puts
Call options by funds: $21.8M | Put options by funds: $26.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Marsico Capital Management
Denver,
Colorado
|
+$41.9M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
+$39.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$39.3M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$36.9M |
| 5 |
O
OrbiMed
New York
|
+$23.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$51.7M |
| 2 |
VAM
Visium Asset Management
New York
|
-$40.3M |
| 3 |
DCM
Daruma Capital Management
New York
|
-$30.9M |
| 4 |
Jennison Associates
New York
|
-$26.3M |
| 5 |
Millennium Management
New York
|
-$25.2M |
PCRX Hedge Fund Activity: Q3 2014 in Review
208 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2014, worth a combined $3.76B — up 8.1% from $3.48B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PCRX positions and 18 closed out — a net gain of 18 holders — while 83 added to existing stakes and 69 trimmed.
The largest buyer was Marsico Capital Management, adding an estimated $41.9M. The largest seller was Wellington Management Group, cutting an estimated $51.7M.
- 208 institutional investors held Pacira BioSciences (PCRX) as of Q3 2014, up from 191 in Q2 2014.
- Funds reported $3.76B of Pacira BioSciences stock for Q3 2014, up 8.1% quarter-over-quarter.
- 36 funds opened new Pacira BioSciences positions in Q3 2014 and 18 closed out, a net change of +18 holders.
- The largest Pacira BioSciences buyer in Q3 2014 was Marsico Capital Management, an estimated $41.9M added.
- The largest Pacira BioSciences seller in Q3 2014 was Wellington Management Group, an estimated $51.7M sold.
Based on aggregated 13F filings for Q3 2014.